Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex (VRTX) Stock Outperforms Industry YTD: Here's Why
Vertex's (VRTX) CF sales are expected to remain strong despite a slight slowdown in the growth rate. Casgevy and suzetrigine (if approved) are set to provide the necessary diversification from the CF franchise.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.
Should You Invest in Vertex (VRTX) Based on Bullish Wall Street Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Vertex Pharmaceuticals, Inc. (VRTX) Q2 2024 Earnings Call Transcript
Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Reshma Kewalramani - Chief Executive Officer, President Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer. Susie Lisa - Senior Vice President, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs David Risinger - Leerink Partners Jessica Fye - J.P.
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
Vertex Pharmaceuticals (VRTX) came out with a quarterly loss of $12.83 per share versus the Zacks Consensus Estimate of a loss of $11.50. This compares to earnings of $3.89 per share a year ago.
Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?
Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
Curious about Vertex (VRTX) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $490.80, denoting a +0.1% change from the preceding trading day.
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
